Literature DB >> 29869700

[Update on heart failure].

J Wintrich1, I Kindermann2, M Böhm2.   

Abstract

Heart failure is one of the leading diseases in internal medicine worldwide. Because of the increase in population aging, the incidence and prevalence of heart insufficiency is rising annually and is now the most frequent individual diagnosis among hospitalized patients in Germany. The mortality rate has recently been reduced, since new pharmacological options, especially the inhibition of neprilysin, have been developed; however, heart failure is still associated with a high mortality and morbidity rate. Thus, guideline-conform treatment is of crucial importance. This review highlights and summarizes the current scientific knowledge on heart failure from 2017 and 2018 based on the guidelines of the European Society of Cardiology. New aspects about heart failure with middle grade limitations of ejection fraction are firstly presented. Subsequently, innovative diagnostic and therapeutic strategies, new pharmacological developments and handling of frequent comorbidities in patients with heart failure are discussed.

Entities:  

Keywords:  Brain natriuretic peptide; Cardiac insufficiency; Comorbidity; Drug therapy; Neprilysin

Mesh:

Substances:

Year:  2018        PMID: 29869700     DOI: 10.1007/s00059-018-4715-1

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  60 in total

1.  The contribution of comorbidities to mortality in hospitalized patients with heart failure.

Authors:  Oliver Riedel; C Ohlmeier; D Enders; A Elsässer; D Vizcaya; A Michel; S Eberhard; N Schlothauer; J Berg; E Garbe
Journal:  Clin Res Cardiol       Date:  2018-02-05       Impact factor: 5.460

2.  Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.

Authors:  Michael Böhm; Robin Young; Pardeep S Jhund; Scott D Solomon; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Karl Swedberg; Michael R Zile; Milton Packer; John J V McMurray
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

3.  The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure.

Authors:  Subodh Verma; John J V McMurray; David Z I Cherney
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

4.  Systolic time intervals in heart failure in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Circulation       Date:  1968-02       Impact factor: 29.690

5.  Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).

Authors:  Michael Böhm; Ana-Cristina Perez; Pardeep S Jhund; Jan C Reil; Michel Komajda; Michael R Zile; Robert S McKelvie; Inder S Anand; Barry M Massie; Peter E Carson; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2014-05-23       Impact factor: 15.534

6.  Low level exercise echocardiography helps diagnose early stage heart failure with preserved ejection fraction: a study of echocardiography versus catheterization.

Authors:  Nadjib Hammoudi; Florent Laveau; Gérard Helft; Nathalie Cozic; Olivier Barthelemy; Alexandre Ceccaldi; Thibaut Petroni; Emmanuel Berman; Michel Komajda; Pierre-Louis Michel; Alain Mallet; Claude Le Feuvre; Richard Isnard
Journal:  Clin Res Cardiol       Date:  2016-09-30       Impact factor: 5.460

7.  Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction.

Authors:  Ashish Rastogi; Eric Novak; Anne E Platts; Douglas L Mann
Journal:  Eur J Heart Fail       Date:  2017-06-14       Impact factor: 15.534

8.  Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.

Authors:  Licette C Y Liu; Adriaan A Voors; John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Yakuan Chen; Barry H Greenberg; Piotr Ponikowski; Peter S Pang; Margaret F Prescott; Tsushung A Hua; Thomas M Severin; Marco Metra
Journal:  Clin Res Cardiol       Date:  2016-03-26       Impact factor: 5.460

9.  Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.

Authors:  Gerasimos Filippatos; Dimitrios Farmakis; Marco Metra; Gad Cotter; Beth A Davison; G Michael Felker; Barry H Greenberg; Tsushung A Hua; Peter S Pang; Piotr Ponikowski; Min Qian; Thomas A Severin; Adriaan A Voors; John R Teerlink
Journal:  Clin Res Cardiol       Date:  2017-02-01       Impact factor: 5.460

10.  Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative.

Authors:  Claudio Ronco; Peter McCullough; Stefan D Anker; Inder Anand; Nadia Aspromonte; Sean M Bagshaw; Rinaldo Bellomo; Tomas Berl; Ilona Bobek; Dinna N Cruz; Luciano Daliento; Andrew Davenport; Mikko Haapio; Hans Hillege; Andrew A House; Nevin Katz; Alan Maisel; Sunil Mankad; Pierluigi Zanco; Alexandre Mebazaa; Alberto Palazzuoli; Federico Ronco; Andrew Shaw; Geoff Sheinfeld; Sachin Soni; Giorgio Vescovo; Nereo Zamperetti; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2009-12-25       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.